Recommended

Alcaftadine, A New Antihistamine With Combined ...

A Multicenter Evaluation Of The Efficacy And Du...

0 votes
Alcaftadine, A New Antihistamine With Combined Antagonist Activity At Histamine H1 , H2 , And H4 Receptors
Author: Annabelle C Gallois-bernos, Robin L Thurmond
Publisher: Derivative Works
12 pages
One time payment: €0.00
Required subscription: Free
Type of publication: Article
ISBN/ISSN: 1178-699X
DOI: 10.2147/JRLCR.S39369
Follow this publisher

Share this publication:

Description:

Abstract: Current therapy for ocular allergy includes H1 antihistamines, mast cell stabilizers, dual action antihistamines (H1 antihistamines + mast cell stabilizers), and steroids. In this report, we describe the in vivo and in vitro characterization of alcaftadine, a recently approved antihistamine that exhibits a distinct set of therapeutic properties. When tested in a guinea pig model of conjunctivitis, alcaftadine prevented immediate allergic responses with an efficacy comparable with that of ketotifen, and was also able to attenuate delayed eosinophil influx with a potency similar to that of dexamethasone. Given recent reports suggesting a possible role for histamine H2 or H4receptors in the etiology of ocular allergy, we examined the binding properties of alcaftadine at all histamine receptor types. Alcaftadine is a high affinity ligand for the H1 receptor, with a pKi (8.5) that is comparable with that of other H1 antihistamines. It also shows an higher affinity for the H2receptor than ketotifen. Alcaftadine exhibited modest binding affinity for the H4 receptor (pKi = 5.8) with no affinity for the H3 receptor. The affinity for the H4 is higher than the value for ketotifen (pKi5). Using a cellular assay of H4 receptor activity, alcaftadine was shown to act as a functional antagonist of H4 receptor signaling. Overall, the studies suggest that alcaftadine is a histamine receptor antagonist with a broad spectrum of antihistamine activity and a unique combination of therapeutic effects. As such, it represents a new therapeutic option for the treatment of allergic conditions.

About the publisher:

We are a publishing house devoted to reuse CC-BY licensed published materials.

 

Using CC-BY licenses:

YOU ARE FREE TO:

  • Adapt — remix, transform, and build upon the material
  • for any purpose, even commercially.
  • The licensor cannot revoke these freedoms as long as you follow the license terms.

UNDER THE FOLLOWING TERMS:

  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others
    from doing anything the license permits.

NOTICES:

  • You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
  • No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

Select a payment method